Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-81201887 versus sham for geographic atrophy secondary to age-related macular degeneration
ISRCTN38641780Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2023
- Modality
- Gene Therapies
01
Overview
Phase 2, randomised, double-blind trial of JNJ-81201887 in age-related macular degeneration (AMD), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline in square root of geographic atrophy lesion area in the study eye at Month 18. Started Mar 2023; status: completed.
02
Drugs
JNJ-81201887
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on ISRCTN38641780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN38641780.